Related references
Note: Only part of the references are listed.Are We There Yet? Impact of the First International Standard for Cytomegalovirus DNA on the Harmonization of Results Reported on Plasma Samples
Jutta K. Preiksaitis et al.
CLINICAL INFECTIOUS DISEASES (2016)
Commutability of the First World Health Organization International Standard for Human Cytomegalovirus
R. T. Hayden et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2015)
Accelerating Drug Development Through Collaboration:The Hepatitis C Drug Development Advisory Group
C. Hutchison et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
Roy F. Chemaly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Francisco M. Marty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial
Mohamed A. Kharfan-Dabaja et al.
LANCET INFECTIOUS DISEASES (2012)
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
Paul D. Griffiths et al.
LANCET (2011)
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
Francisco M. Marty et al.
LANCET INFECTIOUS DISEASES (2011)
The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
A. Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
The Forum for Collaborative HIV Research: A Model for an Integrated and Inclusive Approach to Clinical Research and Drug Development
V. Miller
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Definitions of cytomegalovirus infection and disease in transplant recipients
P Ljungman et al.
CLINICAL INFECTIOUS DISEASES (2002)
Share Paper
